📰 ReutersReutersCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:30:44时区推断·⟳ 抓取 20:33:59·⚡ 决策 08-04 20:55:13 +21m14s·84.0 天前
Rhythm的RM-718获得性下丘脑性肥胖中期数据积极，但属于已处理重复催化
RM-718在7名完成16周治疗患者中BMI平均下降11.6%，事件本身对Rhythm Pharmaceuticals（RYTM.US）管线预期为正面。
📄 原文Reuters↗ 原文
Rhythm Pharmaceuticals (RYTM.O) said on Tuesday its experimental weekly injectable drug helped reduce body weight in pa…
不做 Rhythm Pharmaceuticals（RYTM.US）
同一RM-718获得性下丘脑性肥胖2期初步阳性数据已在2026-08-04 11:01/11:04 UTC被系统处理，本条Reuters 12:30 UTC稿没有新增事实，避免重复推卡和重复建仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 2026-08-04 11:01 UTC首发wire/系统已处理记录非一手系统查重命中“Rhythm公布RM-718在获得性下丘脑性肥胖2期试验初步阳性数据”，早于本条Reuters稿约89分钟。
- 系统查重命中“Rhythm公布RM-718治疗获得性下丘脑肥胖的2期初步积极信号”，确认同一催化已由公司侧披露并处理。
- Reuters转述RM-718初步数据和2Q收入，未带来区别于早前公司披露的新事实。市场反应:Reuters稿称RYTM盘前上涨约5%。
关键理由
- RM-718在7名完成16周治疗患者中BMI平均下降11.6%，事件本身对Rhythm Pharmaceuticals（RYTM.US）管线预期为正面。
- 同一RM-718初步阳性数据已在2026-08-04 11:01 UTC和11:04 UTC由系统处理，12:30 UTC的Reuters稿为同一催化的后续转述。
- 2Q26收入7130万美元、同比增长46.9%，KB命中卖方称Imcivree销售超预期和HO上市动能改善，但这些均随早前财报/业务更新一起披露，未提供新的可交易增量。
主要风险
- 当前不做的核心原因是重复推送；若后续披露更大样本、注册路径或监管沟通结论，才构成新催化。
- RM-718当前样本仍小，且有2名患者因恶心和注射部位问题等不良反应停药，耐受性仍需后续数据验证。
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 1,691 字
Rhythm Pharmaceuticals (RYTM.O) said on Tuesday its experimental weekly injectable drug helped reduce body weight in patients with a rare form of obesity caused by damage to the brain, according to preliminary data from an ongoing mid-stage study.
Shares of the Boston-based company were up 5% in premarket trading.
Here are the details:
The company was testing the drug, RM-718, in patients with acquired hypothalamic obesity, a condition that can develop after surgery or treatment for tumors damages the part of the brain that controls hunger and body weight. It is different from common obesity linked to diet and lifestyle.
Among 11 enrolled patients, the seven who completed 16 weeks of treatment saw their body mass index - a measure of body fat based on height and weight - fall by an average of 11.6%.
"These encouraging results suggest that RM-718 has the potential to deliver clinically meaningful BMI reductions in patients" with the condition, said Rhythm's CEO David Meeker.
RM-718 works by activating a brain receptor called MC4R, which helps control hunger and metabolism.
The company said the level of BMI reduction was similar to results seen with its other obesity drugs, setmelanotide and bivamelagon, over a similar period.
Two patients stopped treatment due to side effects, including nausea and injection site problems, while one patient withdrew from the trial's extension phase.
The company's other drug for acquired hypothalamic obesity, setmelanotide, is sold under the brand name Imcivree as a once-daily injection.
Separately, Rhythm posted second-quarter total revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.
Shares of the Boston-based company were up 5% in premarket trading.
Here are the details:
The company was testing the drug, RM-718, in patients with acquired hypothalamic obesity, a condition that can develop after surgery or treatment for tumors damages the part of the brain that controls hunger and body weight. It is different from common obesity linked to diet and lifestyle.
Among 11 enrolled patients, the seven who completed 16 weeks of treatment saw their body mass index - a measure of body fat based on height and weight - fall by an average of 11.6%.
"These encouraging results suggest that RM-718 has the potential to deliver clinically meaningful BMI reductions in patients" with the condition, said Rhythm's CEO David Meeker.
RM-718 works by activating a brain receptor called MC4R, which helps control hunger and metabolism.
The company said the level of BMI reduction was similar to results seen with its other obesity drugs, setmelanotide and bivamelagon, over a similar period.
Two patients stopped treatment due to side effects, including nausea and injection site problems, while one patient withdrew from the trial's extension phase.
The company's other drug for acquired hypothalamic obesity, setmelanotide, is sold under the brand name Imcivree as a once-daily injection.
Separately, Rhythm posted second-quarter total revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。